XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.4

Note 13 - Segment Information (Tables)

9 Months Ended

Dec. 31, 2020

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

		Three Months Ended December 31, 2020
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Continuous Monitoring				Corporate and Other				Total
Revenues (1)		$	13,077			$	8,971			$	8,711			$	3,413			$	-			$	34,172
Gross profit (loss)		$	9,308			$	5,368			$	4,616			$	1,501			$	(140	)		$	20,653
Reconciling items (2)																							(26,380	)
(Loss) before income taxes																						$	(5,727	)

		Three Months Ended December 31, 2019
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Continuous Monitoring				Corporate and Other				Total
Revenues (1)		$	11,619			$	10,014			$	5,637			$	4,156			$	229			$	31,655
Gross profit (loss)		$	8,101			$	6,526			$	(1,294	)		$	1,488			$	(18	)		$	14,803
Reconciling items (2)																							(19,880	)
(Loss) before income taxes																						$	(5,077	)

		Nine Months Ended December 31, 2020
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Continuous Monitoring				Corporate and Other				Total
Revenues (1)		$	37,696			$	24,209			$	23,791			$	10,277			$	-			$	95,973
Gross profit (loss)		$	28,098			$	14,909			$	15,294			$	4,053			$	(76	)		$	62,278
Reconciling items (2)																							(64,867	)
(Loss) before income taxes																						$	(2,589	)

		Nine Months Ended December 31, 2019
		Sterilization and Disinfection Control				Instruments				Biopharmaceutical Development				Continuous Monitoring				Corporate and Other				Total
Revenues (1)		$	35,823			$	28,518			$	5,637			$	11,059			$	2,442			$	83,479
Gross profit (loss)		$	25,334			$	18,164			$	(1,294	)		$	3,994			$	395			$	46,593
Reconciling items (2)																							(42,471	)
Earnings before income taxes																						$	4,122

Reconciliation of Assets from Segment to Consolidated [Table Text Block]

		December 31, 2020				March 31, 2020
Sterilization and Disinfection Control		$	71,706			$	73,103
Instruments			29,967				31,025
Biopharmaceutical Development			205,769				182,758
Continuous Monitoring			28,834				29,732
Corporate and administrative			285,360				103,588
Total		$	621,636			$	420,206

X

- Definition

Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

+ Details

Name:	us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration